FrancophonIA/ELRC3.0 huggingface dataset:
English: 5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by subcutaneous injection for 3 days.
Estonian: 5 mg enrofloksatsiini kg kehamassi kohta, mis vastab 1 ml ravimile 10 kg kehamassi kohta, kord päevas subkutaanselt 3 päeva.
English: Goat milk (50 mg/ml and 100 mg/ml strengths)
Estonian: Kitsepiim (50 mg/ml ja 100 mg/ml)
English: 2.5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by intramuscular injection for 3 days.
Estonian: 2,5 mg enrofloksatsiini kg kehamassi kohta, mis vastab 1 ml ravimile 10 kg kehamassi kohta, kord päevas intramuskulaarselt 3 päeva.
English: at the recommended therapeutic doses.
Estonian: Retseptiravim.
English: TARGET SPECIES Cattle, sheep, goats and pigs.
Estonian: LOOMALIIGID Veised, lambad kitsed ja sead.
English: Reptiles
Estonian: Närilised
English: IV: Meat and offal: 5 days.
Estonian: Intravenoosselt: lihale ja söödavatele kudedele: 5 päeva.
English: SC: Meat and offal: 10 days.
Estonian: Subkutaanselt: lihale ja söödavatele kudedele: 10 päeva.
English: Cattle (calves), sheep, goats, pigs, dogs and cats.
Estonian: LOOMALIIGID Veis (vasikas), lammas, kits, siga, koer ja kass.
English: Accumulation in plasma does not occur following a treatment interval of 24 h. In milk, most of drug activity consists on ciprofloxacin.
Estonian: Piimas moodustab enamiku toimeainest tsiprofloksatsiin.
English: Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of: Pasteurella multocida, Mycoplasma spp., Actinobacillus pleuropneumoniae.
Estonian: Pasteurella multocida, Mycoplasma spp., Actinobacillus pleuropneumoniae enrofloksatsiini suhtes tundlike tüvede põhjustatud hingamiselundkonna infektsioonide ravi.
English: Residue depletion data were made available and supported a cattle milk withdrawal period of 3 days following an intravenous injection at the recommended dose of 5 mg/kg bw.
Estonian: Olemasolevate jääkide vähenemise andmete põhjal on lehmapiima keeluaeg 3 päeva pärast soovitusliku annuse 5 mg kehamassi kg kohta manustamist veenisisese süstega.
English: Treatment of septicaemia caused by enrofloxacin susceptible strains of Escherichia coli.
Estonian: Escherichia coli enrofloksatsiini suhtes tundlike tüvede põhjustatud septitseemia ravi.
English: 5 mg of enrofloxacin/kg bw, corresponding to 1 ml/5 kg bw, daily by subcutaneous injection for up to 5 days.
Estonian: 5 mg enrofloksatsiini kg kehamassi kohta, mis vastab 1 ml ravimile 5 kg kehamassi kohta, kord päevas subkutaanselt kuni 5 päeva.
English: 5 mg of enrofloxacin/kg body weight (bw), corresponding to 1 ml/5 kg bw, daily by subcutaneous injection for up to 5 days.
Estonian: 5 mg enrofloksatsiini kg kehamassi kohta, mis vastab 1 ml 5 kg kehamassi kohta, kord päevas subkutaanselt kuni 5 päeva.
English: Calves, cattle, pigs, dogs
Estonian: Vasikad, veised, sead, koerad
English: Treatment of infections of the urinary tract caused by enrofloxacin susceptible strains of Escherichia coli.
Estonian: Enrofloksatsiini suhtes vastuvõtlike Escherichia coli tüvedest põhjustatud kuseteede infektsioonide ravi.
English: Treatment of acute severe mastitis caused by enrofloxacin susceptible strains of Escherichia coli.
Estonian: Escherichia coli enrofloksatsiini suhtes tundlike tüvede põhjustatud ägeda raske mastiidi ravi.
English: Pigs
Estonian: Puurilinnud
English: TARGET SPECIES Dogs, cats, pigs (piglets), rabbits, rodents, reptiles and ornamental birds
Estonian: LOOMALIIGID Koer, kass, siga (põrsas), küülik, närilised, roomajad ja puurilinnud.
English: Digestive tract disorders (e.g. diarrhoea) may occur in very rare cases.
Estonian: Väga harvadel juhtudel võivad esineda seedetrakti häired (nt kõhulahtisus).
English: People must not eat, drink or smoke while using the medicine.
Estonian: Ravimi kasutamise ajal ei tohi süüa, juua ega suitsetada.
English: The dispersion should be warmed to 30-35˚C before application.
Estonian: Enne kasutamist tuleb dispersioon soojendada temperatuurini 30-35 °C.
English: Further information on Dany's BienenWohl can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Lisateave ravimi Dany's BienenWohl kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Three weeks of treatment Dany's BienenWohl led to the death of 97 and 95 % of the mites.
Estonian: Kolmenädalane ravi ravimiga Dany's BienenWohl hävitas vastavalt 97% ja 95% lestadest.
English: In case of eye contact, the affected eye should be rinsed thoroughly with water (contact lenses should be removed first).
Estonian: Ravimi sattumisel silma tuleb silma pesta hoolikalt veega (kõigepealt eemaldada kontaktläätsed).
English: The European Medicines Agency concluded that Dany's BienenWohl's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et ravimi Dany's BienenWohl kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: Hands and exposed skin should be washed with soap and plenty of water immediately.
Estonian: Käed ja saastunud nahk tuleb otsekohe pesta seebi ja rohke veega.
English: This medicine is the same as Oxybee, which is already authorised in the European Union (EU).
Estonian: See ravim on samane ravimiga Oxybee, millel juba on Euroopa Liidus müügiluba.
English: Contaminated clothing should be removed immediately.
Estonian: Saastunud kaitserõivad tuleb otsekohe seljast võtta.
English: This authorisation was based on the authorisation granted to Oxybee in 2018 (‘informed consent').
Estonian: Müügiluba põhineb 2018. aastal antud Oxybee müügiloal (teabel põhinev nõusolek).
English: The mite can also help spread viruses and bacteria.
Estonian: Samuti võib varroalest levitada viirusi ja baktereid.
English: Up to 6 ml of Dany's BienenWohl are trickled onto bees in the hive and should only be used when the temperature outside the hives is at least 3˚C.
Estonian: Kuni 6 ml ravimit Dany's BienenWohl niristatakse tarus olevatele mesilastele ning seda tohib kasutada üksnes siis, kui taruväline temperatuur on vähemalt 3 °C.
English: If the product is accidentally swallowed by a person, their mouth should be cleaned with water and water or milk should be drunk, but vomiting should not be induced.
Estonian: Ravimi juhuslikul neelamisel tuleb kannatanu suu pesta veega ja lasta tal juua vett või piima, kuid mitte tekitada oksendamist.
English: Dany's BienenWohl (oxalic acid) EMA/221765/20188
Estonian: Dany's BienenWohl (oksaalhape) EMA/412797/20188
English: What is Dany's BienenWohl and what is it used for?
Estonian: Mis on Dany's BienenWohl ja milleks seda kasutatakse?
English: Medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Seejärel tuleb pöörduda otsekohe arsti poole ja näidata talle pakendi infolehte või etiketti.
English: The most common side effect with Dany's BienenWohl (which may affect more than 1 in 10 bee colonies) is an increased number of bee deaths.
Estonian: Ravimi Dany's BienenWohl kõige sagedam kõrvalnäht (võib esineda enam kui 1 mesilasperes 10st) on mesilaste suurem suremus.
English: The company that makes Oxybee has agreed that its scientific data can be used for Dany's BienenWohl (‘informed consent').
Estonian: Oxybee tootja on andnud nõusoleku, et tema teaduslikke andmeid tohib kasutada ka ravimi Dany's BienenWohl toetuseks (teabel põhinev nõusolek).
English: The effectiveness of Dany's BienenWohl against varroa mites was investigated in two field studies in European countries with different climates.
Estonian: Ravimi Dany's BienenWohl efektiivsust varroalestade hävitamisel uuriti kahes eri kliimatingimustega Euroopa riigis korraldatud väliuuringus.
English: Varroosis is a disease of honey bees caused by infestation with a parasite called varroa mite (Varroa destructor).
Estonian: Varroos on mesilaste haigus, mida põhjustab varroalesta (parasiitlesta Varroa destructor) infestatsioon.
English: Dany's BienenWohl received a marketing authorisation valid throughout the EU on 14 June 2018.
Estonian: Ravimi Dany's BienenWohl müügiluba, mis kehtib kogu Euroopa Liidus, anti 14/06/2018.
English: For more information about using Dany's BienenWohl, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate ravimiga Dany's BienenWohl toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: The varroa mite feeds on the haemolymph (blood) of adult bees and on brood (developing stages of the honey bee) resulting in harm and/or death of bees.
Estonian: Varroalest toitub täiskasvanud mesilaste hemolümfist (verest) ja haudmest (mesilaste valmikueelsed arengujärgud), kahjustades või hävitades mesilasi.
English: Dany's BienenWohl (oxalic acid)
Estonian: Dany's BienenWohl (oksaalhape)
English: Protective clothing, acid resistant gloves and safety glasses should be worn during treatment.
Estonian: Ravimi käsitsemisel tuleb kanda kaitseriõivaid, happekindlaid kindaid ja kaitseprille.
English: Dany's BienenWohl is a medicine used to treat varroosis in honey bee colonies.
Estonian: Dany's BienenWohl on ravim, mida kasutatakse varroosi raviks mesilasperedes.
English: Dany's BienenWohl contains the active substance oxalic acid.
Estonian: Dany's BienenWohl sisaldab toimeainena oksaalhapet.
English: Dany's BienenWohl is highly acidic and could be irritating or corrosive to the skin, eyes and mucous membranes (inner lining of body cavities like the mouth or nose).
Estonian: Dany's BienenWohl on väga happeline ning võib ärritada või söövitada nahka, silmi ja limaskesta.
English: The withdrawal period for honey from honey bees treated with Dany's BienenWohl is ‘zero' days, which means that there is no mandatory waiting time.
Estonian: Ravimiga Dany's BienenWohl ravitud mesilaste mee keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: How oxalic acid works on mites is not well understood but it is thought that the activity of oxalic acid on mites is due to the acidity of the medicine, which kills the mites on contact.
Estonian: Oksaalhappe toimemehhanism lestade vastu ei ole täielikult teada, kuid arvatavasti on oksaalhappe lestavastane toime seotud ravimi happelisusega, mis hävitab lestad kokkupuutel ravimiga.
English: A significant mite infestation can lead to the collapse of a honey bee colony.
Estonian: Suur lestainfestatsioon võib hävitada kogu mesilaspere.
English: In the first study treatment with Dany's BienenWohl was compared to another oxalic acid medicine and to a group with no treatment whilst in the second study treatment with Dany's BienenWohl was compared to a group with no treatment.
Estonian: Esimeses uuringus võrreldi ravimi Dany's BienenWohl kasutamist teise oksaalhapet sisaldava ravimi kasutamisega ning ravi puudumisega (kontrollrühm); teises uuringus võrreldi ravimi Dany's BienenWohl kasutamist ravi puudumisega.
English: Other information about Dany's BienenWohl
Estonian: Muu teave ravimi Dany's BienenWohl kohta
English: Dany's BienenWohl can only be used on colonies without brood and should be used as part of a wider management programme.
Estonian: Ravimit Dany's BienenWohl tohib kasutada üksnes haudmeta mesilasperedes ja seda tuleb kasutada ulatuslikuma tõrjeprogrammi raames.
English: What are the risks associated with Dany's BienenWohl?
Estonian: Mis riskid ravimiga Dany's BienenWohl kaasnevad?
English: An overview of Dany's BienenWohl and why it is authorised in the EU
Estonian: Ravimi Dany's BienenWohl ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: If possible, the use of Dany's BienenWohl should be alternated with another medicine that kills mites in a different way to reduce the chance of the mites developing resistance.
Estonian: Et vähendada lestade resistentsuse tekkeriski, tuleb ravimit Dany's BienenWohl kasutada võimaluse korral vaheldumisi muu ravimiga, mis hävitab lesti teistmoodi.
English: Contact with these areas should be avoided, both directly and by hand-to-mouth or hand-to-eye contact.
Estonian: Vältida tuleb ravimi sattumist otse nahale, silmadesse või limaskestale või käelt suhu ja silma.
English: How is Dany's BienenWohl used?
Estonian: Kuidas ravimit Dany's BienenWohl kasutatakse?
English: Dany's BienenWohl is available as a powder and solution to prepare a bee-hive dispersion (a liquid for use inside the bee hive) and can be obtained without a prescription.
Estonian: Ravimit Dany's BienenWohl turustatakse tarudispersiooni (mesitarus kasutatav vedelik) valmistamise pulbri ja lahusena ning see on käsimüügiravim.
English: How does Dany's BienenWohl work?
Estonian: Kuidas ravim Dany's BienenWohl toimib?
English: What benefits of Dany's BienenWohl have been shown in studies?
Estonian: Milles seisneb uuringute põhjal ravimi Dany's BienenWohl kasulikkus?
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size EU/1/14/955/001 Lymphoseek
Estonian: EMA number (Väljamõeldud) nimetus
English: A risk management plan has been developed to ensure that Silgard is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Silgardi võimalikult ohutu kasutamine.
English: Silgard is given according to official recommendations.
Estonian: Silgardit määratakse vastavalt ametlikele soovitustele.
English: The full EPAR for Silgard can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Silgardi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of
Estonian: Mis meetmed võetakse, et tagada Silgardi ohutu ja efektiivne kasutamine?
English: What is the risk associated with Silgard?
Estonian: Mis riskid Silgardiga kaasnevad?
English: For more information about treatment with Silgard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Silgardiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The CHMP decided that Silgard's benefits are greater than its risks and recommended that it be given
Estonian: Inimravimite komitee otsustas, et Silgardi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Silgard on 20 September 2006.
Estonian: Euroopa Komisjon andis Silgardi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil,
English: Silgard is used in males and females from the age of nine years to protect against the following conditions caused by specific types of human papillomavirus (HPV):
Estonian: Silgardit kasutatakse vähemalt 9-aastastel meestel ja naistel, et kaitsta neid järgmiste haiguste eest, mida põhjustavad inimese papilloomiviiruse teatud tüübid:
English: In studies, the most common side effects with Silgard (seen in more than 1 patient in 10) were headache and reactions at the site of the injection (redness, pain and swelling).
Estonian: Uuringutes olid kõige Silgardi sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) peavalu ning süstekoha reaktsioonid (punetus, valu, turse).
English: human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Estonian: inimese papilloomiviiruse vaktsiin [6., 11, 16. ja 18. tüüp] (rekombinantne,
English: The studies also showed that Silgard provided some protection against lesions in the cervix linked to other cancer-causing types of HPV, including type 31.
Estonian: Samuti näitasid uuringud, et Silgard kaitseb teatud määral emakakaela kahjustuste eest, mis on seotud muude vähkitekitavate papilloomiviiruse tüüpidega, sealhulgas 31. tüübiga.
English: Patients who show signs of an allergy after a dose of Silgard should not receive further doses of the vaccine.
Estonian: Kui patsiendil tekivad pärast Silgardi annuse saamist allergianähud, ei tohi talle järgmisi vaktsiiniannuseid manustada.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas vaktsiini ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas vaktsiini kasutada.
English: The vaccine also contains an ‘adjuvant' (a compound containing aluminium) to stimulate a better
Estonian: Vaktsiin sisaldab parema ravivastuse saamiseks ka adjuvanti (alumiiniumiühendit).
English: This document is a summary of the European public assessment report (EPAR) for Silgard.
Estonian: See on vaktsiini Silgard Euroopa avaliku hindamisaruande kokkuvõte.
English: Silgard contains the purified L1 proteins for HPV types 6, 11, 16 and 18, which are produced by a method known as ‘recombinant DNA technology': they are made by yeast cells into which a gene (DNA) has been introduced that makes them able to produce the L1 proteins.
Estonian: Silgard sisaldab inimese papilloomiviiruse 6., 11., 16. ja 18. tüübi puhastatud L1-valke, mida valmistatakse rekombinant-DNAtehnika abil: neid toodavad pärmirakud, millesse on viidud L1-valkude teket võimaldav geen (DNA).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Silgard, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Kava alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Silgardi ohutusteave, kus on ka tervishoiuspetsialistide ja
English: There were no cases of anal cancer in the study but it is expected that protection against precancerous anal lesions will translate
Estonian: Pärakuvähi juhtumeid ei esinenud, kuid eeldatakse, et pärakupiirkonna vähieelsete kahjustuste kaitse on vähivastane kaitse.
English: In addition, the results confirmed the ability of Silgard to protect against lesions and HPV infection in 24- to 45-year-old women.
Estonian: Lisaks kinnitasid tulemused Silgardi võimet kaitsta 24-45-aastasi naisi kahjustuste ja papilloomiviiruse nakkuse eest.
English: What benefit has Silgard shown during the studies?
Estonian: Milles seisneb uuringute põhjal Silgardi kasulikkus?
English: The study testing Silgard given as 2 doses in girls aged 9 to 13 showed that that the two doses given six months apart were no less effective than the three-dose vaccination: all subjects had developed sufficient amounts of antibodies against HPV one month after their last dose.
Estonian: Uuring, mille käigus anti 9-13-aastastele tüdrukutele Silgardi kaks annust, näitas, et 6-kuulise vahega manustatud vaktsiini kaks annust ei olnud kolmest annusest vähem efektiivsed: kõigil vaktsineeritutel tekkis ühe 1 jooksul pärast viimase annuse saamist piisaval hulgal papilloomiviiruse vastaseid antikehi.
English: For the full list of all side effects reported with Silgard, see the package leaflet.
Estonian: Silgardi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Three studies of Silgard given as three doses looked at the ability of Silgard to prevent infection with HPV types 6, 11, 16 and 18 and genital lesions caused by these HPV types in almost 4,000 women aged between 24 and 45 years, and at the development of antibodies against these HPV types in around 1,700 girls and boys aged between nine and 15 years.
Estonian: Kolmes uuringus vaadeldi kolmes annuses manustatud Silgardi võimet hoida ära papilloomiviiruse 6., 11., 16. ja 18. tüübi nakkust ning nende papilloomiviiruste tüüpidest tingitud suguelundite kahjustusi ligi 4000 naisel vanuses 24-45 aastat, samuti vaadeldi nende papilloomiviiruse tüüpide vastaste antikehade teket ligi 1700 tüdrukul ja poisil vanuses 9-15 aastat.
English: In four main studies of Silgard given as three doses, Silgard was compared with placebo (a dummy vaccine) in almost 21,000 women aged between 16 and 26 years.
Estonian: Kolmeannuselise manustamisskeemiga Silgardi kohta viidi läbi neli põhiuuringut, milles Silgardit võrreldi platseeboga (näiv vaktsiin) ligi 21 000 naisel vanuses 16-26 aastat.
English: Another study in around 800 girls and women compared the effect of two doses of Silgard in girls aged nine to 13 years with the effect of three doses in girls and young women aged 16 to 24 years.
Estonian: Veel ühes ligikaudu 800 tüdruku ja naisega tehtud lisauuringus võrreldi kahes annuses manustatud Silgardi efektiivsust 9-13-aastastel tüdrukutel ja kolmes annuses manustatud Silgardi efektiivsust 1624-aastastel tüdrukutel ja noortel naistel.
English: For people aged nine to thirteen years, Silgard can be given as two doses six months apart.
Estonian: 9-13-aastastele patsientidele manustatakse Silgardit kahe annusena, jättes nende vahele 6 kuud.
English: In the four studies in 21,000 women, out of the more than 8,000 women vaccinated with Silgard who had never been infected by HPV types 6, 11, 16 or 18 before, one woman developed a precancerous lesion in the cervix that might have been due to HPV type 16 or 18.
Estonian: 21 000 naisel läbi viidud neljas uuringus tekkis ühel enam kui 8000st Silgardiga vaktsineeritud naisest, kes ei olnud varem papilloomiviiruse 6., 11., 16. ja 18. tüübiga nakatunud, arvatavasti papilloomiviiruse 16. või 18. tüübist tingitud vähieelne emakakaela kahjustus.
English: Finally, a main study in around 4,000 boys and men from 16 to 26 years of age compared the vaccine against placebo to test the vaccine's effect in preventing genital warts, precancerous anal lesions and anal cancer.
Estonian: Põhiuuringus, milles osales ligikaudu 4000 poissi ja meest vanuses 16-26 aastat, võrreldi vaktsiini platseeboga, et kontrollida vaktsiini toimet kondüloomide, pärakupiirkonna vähieelsete kahjustuste ja
English: The studies also showed that the vaccine stimulates the production of sufficient amounts of antibodies against HPV in girls and boys aged between nine and 15 years.
Estonian: Samuti näitasid uuringud, et vaktsiin stimuleerib 9-15-aastastel tüdrukutel ja poistel piisaval hulgal papilloomiviiruse vastaste antikehade
English: For people aged fourteen or above, Silgard is normally given according to a three-dose schedule with the second dose given two months after the first and the third given four months after the second..
Estonian: Vähemalt 14-aastastele patsientidele manustatakse tavaliselt Silgardi kolm annust, millest teine annus manustatakse 2 kuud pärast esimest ja kolmas annus manustatakse 4 kuud pärast teist annust.
English: In the study boys and men, there were 3 cases genital lesions among around 1,400 patients given the vaccines compared with 32 cases among around 1,400 given placebo.
Estonian: Poiste ja meeste uuringus esines suguelundite kahjustusi 3 patsiendil ligi 1400st, keda vaktsineeriti Silgardiga ja 32 patsiendil ligi 1400st, keda vaktsineeriti platseeboga.
English: In the three studies on genital lesions 2 women out of almost 8,000 in the Silgard group developed genital warts, and there were no cases of precancerous lesions of the vulva or the vagina.
Estonian: Suguelundite kahjustuste kolmes uuringus esines Silgardiga vaktsineeritud rühmas kahel naisel (ligi 8000st) kondüloome ning vähieelseid tupe ja häbeme kahjustusi ei esinenud.
English: It is recommended that individuals who receive the first dose of Silgard should complete the dosing regimen with Silgard.
Estonian: Esimese annuse saanud patsientidel on soovitatav viia kogu Silgardi vaktsineerimiskuur lõpule.
English: A similar effect of Silgard was seen when the analysis also included lesions of the cervix due to the other two HPV types (types 6 and 11).
Estonian: Sarnane Silgardi toime ilmnes ka papilloomiviiruse 6. ja 11. tüübist tingitud emakakaela kahjustuste analüüsimisel.